Tag Archives: Investors

RESI San Francisco Asia Pacific Investors Panel

26 Jan

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:

Key takeaway points from the panel:

  • Chinese investors are pushed to look overseas by the following forces: asset price, scarcity of high-quality products, and scarcity of exit in the public market. Many of them are seeking one or more of the following factors from US early stage companies: cutting-edge technologies, large sales potential in their domestic markets, and access to the US market.
  • The Chinese government’s new currency restriction has impacted some transactions and created uncertainty in the future. Dual currency funds (firms that manage domestic RMB and offshore USD funds) are less affected.
  • To engage a Chinese partner, it is key to identify a ‘China hook’ of your product. Large patient population is only one factor. Regulatory process, medical practice, and reimbursement should also be considered.
  • A good partnership can come in different forms: direct investment, licensing, joint venture, M&A, etc. Entrepreneurs should work with experienced investors to form a partnership that is most suitable for their product sector and stage.

“Know your investors and live your business plan” – BioWorld Highlights RESI @ JPM

19 Jan

By Lucy Parkinson, Director of Research, LSN

As RESI attracts increasing media attention, BioWorld have provided some highlights and analysis on RESI’s content. This roundup focuses on two of RESI’s investor panels: Biotech Angels and Tales From The Road. Between these two sessions, RESI attendees caught a high-level view inside an early stage life science deal from both sides. On one side of the table, angel investors explore how they hunt for deals and work with startups after investment. On the other side, successful CEOs share their stories of finding and vetting investors who are a fit for their companies. You can read more at BioWorld: http://www.bioworld.com/content/know-your-investors-and-live-your-business-plan

RESI San Francisco Panel Announcement: Tech Giants in Healthcare

29 Dec

By Michael Quigley, VP of Market Research, LSN

mike-2

Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.

Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:

  • Iana Dimkova, Senior Associate, Healthcare, GE Ventures
  • Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
  • Rich Wilmot, Head of Corporate Venturing, Philips
  • Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS

In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.

RESI San Francisco Panel Announcement: Big Pharma

10 Nov

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As we gear up for the biggest RESI event of the year, during the heavily anticipated JPM week, we’re happy to once again announce the Big Pharma panel. This is typically one of the most popular panels at the RESI conference, and for good reason – large pharmaceutical and biotech companies, through a variety of deal structures, are looking earlier and earlier for assets, but tend to represent a daunting challenge for entrepreneurs seeking to successfully engage and navigate.

Senior-level executives from some of the world’s top pharmaceutical companies will provide some color around their process and strategy, and how entrepreneurs can best prepare to present to and work with organizations like theirs.

Big Pharma panelists will include the following:

  • Monica Viziano, Sr. Director, Business Development, Gilead
  • Barbara Sosnowski, VP External R&D Innovation, Pfizer
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Christian Schubert, Director, Corporate Development & Strategy, Biogen
  • Jeremy Grunstein, Executive Director, Business Development, Amgen

By registering for RESI San Francisco on January 10 (Tuesday of JPM week), you’ll be able to listen to this panel live and gain insight into the dynamics of partnering with a strategic player as well as experience numerous opportunities to expand your network in the life sciences and learn more about the fundraising process in general.

resi-san-francisco-2017

Tips on How to Improve Your RESI Innovation Challenge Application – And Your Investor Pitch

3 Nov

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

The LSN Innovation Challenge is a competition held at every RESI Conference that provides early-stage companies with a unique opportunity to showcase their technologies at a meeting typically attended by 400 – 500 investors. LSN invites thirty top-tier early-stage fundraising companies to pitch their technologies in a poster format at a venue that provides ready access to a range of investors. The RESI Innovation Challenge has become an exciting event at each RESI meeting that attracts a lot of attention from entrepreneurs and investors alike.

The LSN scientific review team spends a lot of time reviewing applications, that now number in the hundreds, prior to selecting the top thirty. As the Innovation Challenge application deadline draws near (November 18th, folks!), we thought we would share with you how we select the winners. LSN’s scientific review team has compiled some tips on how to submit a compelling Innovation Challenge application.

Keep in mind that, while the following is focused on the Innovation Challenge application itself, the criteria and the tips we provide are also relevant for the fundraising process. Many of the questions we ask are similar to what investors will ask when you are out fundraising.

How do you achieve a high score on your application?

The LSN scientific review team uses a detailed rubric with a 200-point scoring system. Companies are stack-ranked on their scores and we invite the top 30 to present at RESI. Our evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A high scoring company might have a transformational technology that can address a high unmet need using a novel approach or target. In addition to innovation, differentiation, unmet need, and market fit, investors are keenly interested in a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners (if the company is at that stage). LSN also looks at whether the company has “investor-ready” marketing material (executive summary, pitch deck, website).

Application Tips

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure to understand and answer the questions fully. Instead of saying “my company has a proprietary treatment for many critical illnesses”, it would be much clearer to say, “we are developing an IND-ready small molecule asset for breast cancer by activating natural killer cells.”

Lack of clarity will diminish your chances to participate in the Innovation Challenge.

Be realistic with your answers.

The team frequently reviews applications that don’t adequately highlight the competition. Novel products typically do have competitor’s products that precede them. The key point is to highlight how your technology differentiates itself from competitors.

For example, competitors for your disease-modifying therapeutic may only treat disease symptoms. You should identify existing therapeutics and highlight how your technology may offer a disease-modifying alternative.

Explain your current company status in detail.

Outline your current status, as well as provide your view of the strategic direction of your company. When describing your management team, avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Summarize near-term and long-term strategy.

If you do not have certain criteria, such as a strategic alliance or IP, it’s OK. State your current standing and provide what steps you are currently taking to reach that milestone.

For Alliances and Collaborations, summarize key relationships – focus on KOLs, medical centers, big pharma, and clinical and manufacturing partners. If there is no signed agreement, stating any verbal relationships would be helpful. If you don’t have issued patents yet, state how many patent applications you have filed or are planning to file. Providing us your strategy is better than a simple yes or no.

Provide enough information but don’t go over-board.

Spend more than 5 minutes on this application, but don’t spend 5 hours. Your answers should be brief, but reasonably detailed. We have received hastily done applications that lacked key information—which quickly received a low score and didn’t make the cut. The questions are all straight-forward that you should be comfortable in answering and have down pat. Remember, your executive summary should include answers to many of these questions already.

Send us your marketing material.

If you have marketing material, send it. We do read it and it can help your score. This includes your pitch deck, executive summary, website, videos – any supplemental material that can boost our understanding of your technology and whether your company is investor-ready. The application provides limited space. While this forces you to get straight to the point, supplemental material explains what an application sometimes doesn’t allow (i.e. figures, graphs, pipeline, non-confidential data, etc.)

Overall, applying for the Innovation Challenge is great practice for fundraising companies. For those who have yet to apply, be sure to take note of these suggestions and apply here before November 18th!

237521341025992000

resi-san-francisco-2017

RESI San Francisco 2017 Panel Announcement: Early Stage Therapeutics Investors

27 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

The critical early years of drug development after lead compound selection see pre-clinical studies, IND-filing, and the design and implementation of clinical trials. While navigating the regulatory needs of the FDA may seem enough of a challenge, entrepreneurs must also consider how their drug addresses the needs of investors. Capital intensity, endpoint selection, timelines to inflection points – these are just a few topics beyond the scientific data that LSN researchers have discussed the importance of with investors.

Understanding what investors are looking for in the deal and business plan structure can help entrepreneurs immensely in their approach to funding. LSN is pleased to announce the Early Stage Therapeutics Investors panel for RESI SF 2017, where five therapeutics investors will share their perspective on evaluating deals and answer audience questions.

Joining moderator Doug Fisher, Partner, InterWest Partners:

Check out these investors’ bios, and if you haven’t registered yet, do so here or get in touch with us by reaching out to the RESI team at RESI@lifesciencenation.com.

237521341025992000

resi-san-francisco-2017

The Investors You’ll Meet at RESI San Francisco

20 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

Registration for RESI SF 2017 has been open for only a little over a month, and already 239 investors across 158 firms are registered. To illustrate who these 158 firms are, the below shows a breakdown of registered investment firm categories. VC firms have a large showing, followed by Corporate Venture groups and large pharmaceutical/biotech companies active in equity investing and early stage partnering.

 

Click to See More Confirmed Investors

Of the 239 investors registered thus far, 67% have a decision maker role at their firm, such as Director, VP, Partner or a C-Suite title. Only 16% are entry level investment professionals responsible for sourcing and preliminary screening. Of the remainder, most hold other managerial and sourcing roles; in addition, 6% of the investor attendees are angel investors. This abundance of active early stage life science investors and decision makers is unparalleled. Check out the below list of investors that have already registered, and keep in mind that many more will be added in the months leading up to the date of RESI SF on January 10th. We add new confirmed investors to the website every few days – keep up to date here.  You have until Friday October 21st to sign up for RESI at the Earlybird rate – that’s tomorrow!

162801425610010374

resi-san-francisco-2017